These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 15221469

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
    Shiran MS, Isa MR, Sherina MS, Rampal L, Hairuszah I, Sabariah AR.
    Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
    [Abstract] [Full Text] [Related]

  • 3. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways.
    Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W, Ren YB, Su B, Cao GW, Yang Y, Yan YQ, Shen F, Wu MC, Feng GS, Wang HY.
    Hepatology; 2011 Jan; 53(1):181-92. PubMed ID: 21254169
    [Abstract] [Full Text] [Related]

  • 4. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
    Radwan NA, Ahmed NS.
    Diagn Pathol; 2012 Oct 30; 7():149. PubMed ID: 23111165
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.
    Röcken C, Licht J, Roessner A, Carl-McGrath S.
    J Clin Pathol; 2005 Oct 30; 58(10):1069-75. PubMed ID: 16189153
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
    Tsuji M, Kashihara T, Terada N, Mori H.
    Pathol Int; 1999 Apr 30; 49(4):310-7. PubMed ID: 10365850
    [Abstract] [Full Text] [Related]

  • 9. p28(GANK) prevents degradation of Oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis.
    Qian YW, Chen Y, Yang W, Fu J, Cao J, Ren YB, Zhu JJ, Su B, Luo T, Zhao XF, Dai RY, Li JJ, Sun W, Wu MC, Feng GS, Wang HY.
    Gastroenterology; 2012 Jun 30; 142(7):1547-58.e14. PubMed ID: 22387393
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
    Al-Muhannadi N, Ansari N, Brahmi U, Satir AA.
    Ann Hepatol; 2011 Jun 30; 10(4):508-15. PubMed ID: 21911893
    [Abstract] [Full Text] [Related]

  • 16. p28GANK inhibits endoplasmic reticulum stress-induced cell death via enhancement of the endoplasmic reticulum adaptive capacity.
    Dai RY, Chen Y, Fu J, Dong LW, Ren YB, Yang GZ, Qian YW, Cao J, Tang SH, Yang SL, Wang HY.
    Cell Res; 2009 Nov 30; 19(11):1243-57. PubMed ID: 19736567
    [Abstract] [Full Text] [Related]

  • 17. Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma.
    Tan L, Fu XY, Liu SQ, Li HH, Hong Y, Wu MC, Wang HY.
    Liver Int; 2005 Jun 30; 25(3):667-76. PubMed ID: 15910504
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.